Journal article

Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer

Paul L Mitchell, Adam Broad, Mark A Rosenthal, Peter Galettis, Rick Abraham, Ivon Burns, Stephen Clarke, Alvin Milner, Juliana Diiulio, Matthew Links

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY-BLACKWELL | Published : 2011

Abstract

AIM: This multicentre phase II trial examined the combination of gemcitabine and oxaliplatin in patients with advanced non-small cell lung cancer (NSCLC). The effect of sequence administration was randomized and pharmacokinetics (PK) assessed. METHODS: Eligible patients had stage IIIB or IV or recurrent NSCLC, no prior chemotherapy, World Health Organization performance status ≤2 and measurable disease. Treatment comprised: gemcitabine (1250 mg/m(2)) and oxaliplatin (70 mg/m(2)), each given on days 1 and 8 of a 21-day cycle. Patients were randomized 1:1 to the sequencing of the two drugs for the duration of their treatment. The primary end-point was response rate (RR). Secondary end-points i..

View full abstract